61 completed, 9 recruiting, 8 terminated, 8 unknown. 38 Phase 2, 28 Phase 1, 17 Phase 3, 16 Not applicable, 1 Early Phase 1.
Follow Peanut Allergy: new trials by email Literature Review of Peanut Allergy trials Research Report on Peanut Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy | Phase 3 | Recruiting | Novartis Pharmaceuticals | 576 | 2026-08-27 | 2026-10-13 |
| Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy Autoclaved peanut oral immunotherapy, Blanched peanut oral immunotherapy - Peanut Allergy | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 57 | 2026-08-01 | 2026-03-03 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| Safety of MOON101 for the Treatment of Peanut Allergy Dose A, Dose B, Dose C - Peanut Allergy | Phase 1 | Suspended | Moonlight Therapeutics, Inc. | 40 | 2026-06-29 | 2026-10-16 |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) DBV712 250 mcg, Placebo - Allergy, Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 480 | 2025-06-24 | 2026-07-22 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 IGNX001, Placebo - Peanut Allergy | Phase 1 | Completed | IgGenix Australia Pty Ltd | 32 | 2024-09-01 | 2025-11-14 |
| Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy Peanut Oral Powder [PEANUT POWDER], Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin) - Peanut Allergy | Phase 2 | Withdrawn | Murdoch Childrens Research Institute | 2024-05-01 | 2024-09-19 | |
| Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT) - Allergy, Peanut, Peanut Allergy | Phase 2 | Recruiting | Rima Rachid | 37 | 2023-06-08 | 2025-08-24 |
| Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy Assessment of peanut, tree nuts and sesame allergy - Atopic Dermatitis, Food Allergy | Unknown | Medical University of Warsaw | 240 | 2023-04-17 | 2023-04-19 | |
| A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy PVX-108, Placebo - Peanut Allergy, Peanut Hypersensitivity | Phase 2 | Active not recruiting | Aravax Pty Ltd | 95 | 2023-02-09 | 2026-11-02 |
| Using Commonly Available Food Products To Treat Food Allergy Peanut in common foods or supermarket-sourced cow's milk (CM) - IgE-Mediated Cow Milk Allergy, Peanut Allergy | Not applicable | Active not recruiting | University of Southampton | 216 | 2023-01-19 | 2026-05-13 |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects VLP Peanut, Placebo - Peanut Allergy | Phase 1 | Active not recruiting | Allergy Therapeutics | 46 | 2022-10-17 | 2026-03-13 |
| Immune-supportive Diet and Gut Permeability in Allergic Children Immune-supportive diet, Standard care - Peanut Allergy, Nut Allergy | Not applicable | Recruiting | Onze Lieve Vrouwe Gasthuis | 132 | 2022-09-08 | 2025-05-01 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| CNP-201 in Subjects With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 15 | 2022-03-14 | 2023-12-20 |
| Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety Food allergy desensitization / Oral Immunotherapy - Peanut Allergy, Milk Allergy, Cow's | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 360 | 2022-03-01 | 2026-05-07 |
| Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy Abatacept, Placebo, Peanut oral immunotherapy - Peanut Allergy | Phase 2 | Completed | Philippe Bégin | 14 | 2022-03-01 | 2024-11-27 |
| Induction of Sustained Unresponsiveness to Peanuts Using High- and Low-dose Peanut Oral Immunotherapy High dose OIT, Low dose OIT - Peanut Allergy | Not applicable | Unknown | Medical University of Warsaw | 40 | 2022-02-05 | 2023-08-01 |
Showing 20 of 101. Sign in to see all of them.
Peanut Hypersensitivity (101) · Food Hypersensitivity (35) · Hypersensitivity (18) · Nut Hypersensitivity (5) · Hypersensitivity, Immediate (4) · Anaphylaxis (3) · Egg Hypersensitivity (3) · Milk Hypersensitivity (3) · Dermatitis, Atopic (2) · Immune System Diseases (2) · Eczema (1) · Nut and Peanut Hypersensitivity (1) · SeSAME syndrome (1) · Severe combined immunodeficiency with sensitivity to ionizing radiation (1)
Nut and Peanut Hypersensitivity (100) · Immune System Diseases (99) · Hypersensitivity, Immediate (97) · Hypersensitivity (83) · Food Hypersensitivity (66) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Skin Diseases (2) · Skin Diseases, Eczematous (2) · Skin Diseases, Genetic (2) · Skin and Connective Tissue Diseases (2)
Omalizumab (6) · Capsules (4) · Immunotherapy (3) · dupilumab (3) · Abatacept (1) · Anti-Bacterial Agents (1) · Diet (1) · Fecal Microbiota Transplantation (1) · Food Coloring Agents (1) · Histamine Antagonists (1) · Observation (1) · Prebiotics (1) · Probiotics (1) · Ranitidine (1) · Standard of Care (1)
DBV Technologies (12) · Aimmune Therapeutics, Inc. (10) · Johns Hopkins University (5) · Massachusetts General Hospital (5) · University of North Carolina, Chapel Hill (5) · University Hospital, Montpellier (4) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · Medical University of Warsaw (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Stanford University (3) · Astellas Pharma Global Development, Inc. (2) · COUR Pharmaceutical Development Company, Inc. (2) · HAL Allergy (2) · Lille Catholic University (2) · Novartis Pharmaceuticals (2)
United States (61) · Canada (21) · France (13) · United Kingdom (11) · Germany (8) · Ireland (8) · Netherlands (8) · Australia (7) · Spain (7) · Sweden (6) · Italy (4) · Poland (4) · Denmark (2) · Switzerland (2) · Hong Kong (1)
Wayne G Shreffler, MD, PhD (5) · Edwin Kim, MD (3) · Robert Wood, MD (3) · Wesley Burks, MD (3) · Jerry Staser (2) · Scott Sicherer, MD (2) · Susan Waserman, MD (2) · Alia J Crum, PhD (1) · Ana Tabar, PhD, MD (1) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BD MD (1)
PMID 34389504, PMID 34320250, PMID 36915184, PMID 38814736, PMID 30978404, PMID 32414772, PMID 33463542, PMID 37163622, PMID 38010254, PMID 19226304, PMID 19477496, PMID 19577283, PMID 21414048, PMID 25925398, PMID 26920463, PMID 27883239, PMID 29136445, PMID 29700872, PMID 29709643, PMID 30449234, PMID 30794314, PMID 31329313, PMID 31442495, PMID 31522849, PMID 31676085, PMID 31723064, PMID 32434067, PMID 32502548, PMID 32702315, PMID 32783912, PMID 33259921, PMID 34669990, PMID 34755130, PMID 34813505, PMID 37973545, PMID 38282192, PMID 38320526, PMID 38407394, PMID 38804779, PMID 39673367, PMID 39673452, PMID 39756833, PMID 39842774, PMID 39928078, PMID 39956162, PMID 40023371, PMID 40204253, PMID 40268292, PMID 41488220, PMID 41615410
2018 (3), R01AT004435 (2), U19AI095261 (2), 2019 (1), U01AI125290 (1), U19AI070345 (1), U19AI104209 (1), U19AI136053 (1), U44AI165328 (1)